Amongst IDH-mutant gliomas, the homozygous deletion of CDKN2A/B has been shown to be an important marker for adverse clinical outcomes and this has been reflected in the updated grading scheme of the IDH-mutant astrocytoma [1]. The gene discussed is IDH2; the disease is central nervous system cancer.